title: Agastache rugosa leaf extract inhibits the iNOS expression in ROS 17/2.8 cells activated with TNF-alpha and IL-1beta.
abstract: It has been suggested that nitric oxide (NO) derived from inducible nitric oxide synthase (iNOS) may act as a mediator of cytokine-induced effects on bone turn-over. NO is also recognized as an important factor in bone remodeling, i.e., participating in osteoblast apoptosis in an arthritic joint. The components of Agastache rugosa are known to have many pharmacological activities. In the present study, we investigated the effects of Agastache rugosa leaf extract (ELAR) on NO production and the iNOS expression in ROS 17/2.8 cells activated by a mixture of inflammatory cytokines including TNF-alpha and IL-1beta. A preincubation with ELAR significantly and concentration-dependently reduced the expression of iNOS protein in ROS 17/2.8 cells activated with the cytokine mixture. Consequently, the NO production was also significantly reduced by ELAR with an IC50 of 0.75 mg/mL. The inhibitory mechanism of iNOS induction by ELAR prevented the activation and translocation of NF-kappaB (p65) to the nucleus from the cytosol fraction. Furthermore, ELAR concentration-dependently reduced the cellular toxicity induced by sodium nitroprusside, an NO-donor. These results suggest that ELAR may be beneficial in NO-mediated inflammatory conditions such as osteoporosis.
authors.affiliation: Department of Pharmacology, College of Medicine, and Institute of Health Sciences, Gyeongsang National University, Jinju 660-751, Korea.
authors.forename: Hwa Min
authors.initials: HM
authors.lastname: Oh
authors.forename: Young Jin
authors.initials: YJ
authors.lastname: Kang
authors.forename: Sun Hee
authors.initials: SH
authors.lastname: Kim
authors.forename: Young Soo
authors.initials: YS
authors.lastname: Lee
authors.forename: Min Kyu
authors.initials: MK
authors.lastname: Park
authors.forename: Ja Myung
authors.initials: JM
authors.lastname: Heo
authors.forename: Jin ji
authors.initials: Jj
authors.lastname: Sun
authors.forename: Hyo Jung
authors.initials: HJ
authors.lastname: Kim
authors.forename: Eun Sil
authors.initials: ES
authors.lastname: Kang
authors.forename: Hye Jung
authors.initials: HJ
authors.lastname: Kim
authors.forename: Han Geuk
authors.initials: HG
authors.lastname: Seo
authors.forename: Jae Heun
authors.initials: JH
authors.lastname: Lee
authors.forename: Hye Sook
authors.initials: HS
authors.lastname: Yun-Choi
authors.forename: Ki Churl
authors.initials: KC
authors.lastname: Chang
mesh_terms: D031327:Agastache / Q000737:chemistry*; D000818:Animals; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D007375:Interleukin-1 / Q000494:pharmacology* / Q000502:physiology; D016328:NF-kappa B / Q000378:metabolism; D009569:Nitric Oxide / Q000096:biosynthesis; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D010936:Plant Extracts / Q000494:pharmacology; D018515:Plant Leaves / Q000737:chemistry*; D021381:Protein Transport; D051381:Rats; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology* / Q000502:physiology
chemical_list: D007375:Interleukin-1; D016328:NF-kappa B; D010936:Plant Extracts; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat